Summary

The body fluid analysis market is projected to grow from USD 2.62 billion in 2026 to USD 3.65 billion by 2031, growing at a CAGR of 6.9%. The increasing prevalence of neurological disorders such as Alzheimer's disease and Parkinson's disease is driving demand for cerebrospinal fluid (CSF) biomarker testing, while the growing incidence of musculoskeletal disorders and periprosthetic joint infections is expanding the use of synovial fluid analysis. Furthermore, advancements in automated analyzers, flow cytometry, immunoassays, and molecular diagnostic technologies are improving the accuracy, efficiency, and standardization of specialty body fluid testing. These innovations are enabling healthcare providers to make more informed diagnostic and treatment decisions, thereby supporting market growth.

“The clinical diagnostics segment is expected to account for the largest share of the body fluid analysis market, by application, during the forecast period.”
Depending on the application, the body fluid analysis market is classified into clinical diagnostics, forensics, and research applications. The clinical diagnostics segment accounts for the largest market share due to the increasing use of body fluid analysis for the diagnosis and monitoring of neurological disorders, infections, cancers, inflammatory conditions, and reproductive health disorders. Clinical laboratories and hospitals extensively utilize technologies such as flow cytometry, immunoassays, clinical chemistry, and molecular diagnostics to analyze cerebrospinal fluid (CSF), pleural fluid, peritoneal fluid, synovial fluid, and other specialty body fluids. Additionally, the growing emphasis on early disease detection, precision diagnostics, and evidence-based clinical decision-making continues to drive demand for body fluid analysis in routine healthcare settings, making clinical diagnostics the largest and fastest-growing application segment of the market.
“The clinical chemistry is likely to capture the largest share of the body fluid analysis market throughout the forecast period.”
The global body fluid analysis market can be segmented by technology into microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction (PCR), and other technologies. Among these, the clinical chemistry segment is likely to account for the largest market share throughout the forecast period. Clinical chemistry testing remains a fundamental component of routine body fluid evaluation due to its established clinical utility, broad availability across healthcare facilities, and ability to support rapid diagnostic decision-making. Furthermore, continuous advancements in automated chemistry analyzers, increasing laboratory testing volumes, and growing demand for standardized diagnostic workflows are expected to support the continued adoption of clinical chemistry-based body fluid analysis worldwide.
“Asia Pacific: The fastest-growing market for body fluid analysis testing from 2026 to 2031”
The global body fluid analysis market is divided into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. Asia Pacific is projected to grow at the highest regional CAGR from 2026 to 2031. Japan has a large aging population driving demand for CSF-based neurodegenerative diagnostics. China is expanding hospital laboratory capacity through national health modernization programs. India’s network of tertiary-care hospitals and private diagnostic centers is adopting automated body fluid analysis systems.
The break-up of the profile of primary participants in the body fluid analysis market:
・By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier - 30%
・By Designation: C-level Executives - 27%, Directors – 18%, and Others - 55%
・By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and Middle East & Africa - 4%
Sysmex Corporation (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); Danaher Corporation (US); bioMérieux SA (France); Abbott Laboratories (US); Thermo Fisher Scientific Inc. (US); QIAGEN N.V. (Netherlands); Revvity, Inc. (US); Siemens Healthineers AG (Germany); Becton, Dickinson and Company (US); HORIBA, Ltd. (Japan); Bio-Rad Laboratories, Inc. (US); and DiaSorin S.p.A. (Italy) are some of the key players in the body fluid analysis market.
Research Coverage:
This research report categorizes the body fluid analysis market by product (consumables and instruments), by technology (microscopic examination, clinical chemistry, flow cytometry, immunoassay, polymerase chain reaction, and other technologies), by type (collection devices and diagnostic products), by fluid type (cerebrospinal fluid, pleural fluid, peritoneal fluid, synovial fluid, semen, and pericardial fluid), by application (clinical diagnostics, forensic, and research), by end user (hospital laboratories, diagnostic laboratories, forensic laboratories, academic and research institutes, and pharmaceutical and biotechnology companies), and by region (North America, Europe, Asia Pacific, Latin America, and Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the body fluid analysis market. A detailed analysis of the key industry players has been done to provide insights into their business overview; solutions; key strategies such as acquisitions, agreements, and product & service launches; and recent developments associated with the body fluid analysis market. Competitive analysis of upcoming startups in the body fluid analysis market ecosystem is covered in this report.
Reasons to Buy This Report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall body fluid analysis market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
・Analysis of key drivers (growing global disease burden, increasing prevalence of reproductive health conditions and infertility, growing awareness of early disease detection), restraints (lack of standardized reimbursement structures, high cost of instruments and consumables, shortage of skilled laboratory personnel), opportunities (expansion potential across emerging economies, advancements in diagnostic technologies), and challenges (stringent and varying regulatory requirements, supply chain disruptions for reagents and kits) influencing the growth of the body fluid analysis market.
・Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the body fluid analysis market.
・Market Development: Comprehensive information about lucrative markets—the report analyzes the body fluid analysis market across varied regions.
・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the body fluid analysis market
・Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Danaher (US); F. Hoffmann-La Roche Ltd. (Switzerland); Thermo Fisher Scientific Inc. (US); Becton, Dickinson and Company (US); and Abbott (US).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 30
1.1 STUDY OBJECTIVES 30
1.2 MARKET DEFINITION 30
1.3 STUDY SCOPE 31
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 31
1.3.2 INCLUSIONS AND EXCLUSIONS 32
1.3.3 YEARS CONSIDERED 32
1.3.4 CURRENCY CONSIDERED 32
1.4 STAKEHOLDERS 33
1.5 SUMMARY OF CHANGES 33
2 EXECUTIVE SUMMARY 35
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 35
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 36
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 37
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 38
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 39
3 PREMIUM INSIGHTS 40
3.1 BODY FLUID ANALYSIS MARKET OVERVIEW 40
3.2 BODY FLUID ANALYSIS MARKET, BY PRODUCT, 2026 VS. 2031 40
3.3 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY, 2026 VS. 2031 41
3.4 BODY FLUID ANALYSIS MARKET, BY TYPE, 2026 VS. 2031 41
3.5 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE, 2026 VS. 2031 42
3.6 BODY FLUID ANALYSIS MARKET, BY APPLICATION, 2026 VS. 2031 42
3.7 BODY FLUID ANALYSIS MARKET, BY END USER, 2026 VS. 2031 43
3.8 BODY FLUID ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 43
4 MARKET OVERVIEW 44
4.1 INTRODUCTION 44
4.2 MARKET DYNAMICS 44
4.2.1 DRIVERS 45
4.2.1.1 Growing global infectious disease, inflammatory disease, and cancer burden necessitating body fluid analysis 45
4.2.1.2 Increasing prevalence of reproductive health conditions and infertility 45
4.2.1.3 Growing awareness of early disease detection 46
4.2.2 RESTRAINTS 47
4.2.2.1 Limited and inconsistent reimbursement for advanced body
fluid testing 47
4.2.2.2 High cost of instruments and consumables 47
4.2.2.3 Shortage of skilled laboratory personnel 48
4.2.3 OPPORTUNITIES 49
4.2.3.1 Expansion potential across emerging economies 49
4.2.3.2 Advancements in diagnostic technologies 49
4.2.4 CHALLENGES 50
4.2.4.1 Stringent and varying regulatory requirements 50
4.2.4.2 Supply chain disruptions for reagents and kits 51
4.3 UNMET NEEDS AND WHITE SPACES 52
4.3.1 UNMET NEEDS IN BODY FLUID ANALYSIS MARKET 52
4.3.2 WHITE SPACE OPPORTUNITIES 53
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 54
4.4.1 INTERCONNECTED MARKETS 54
4.4.2 CROSS-SECTOR OPPORTUNITIES 55
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 56
4.5.1 KEY MOVES AND STRATEGIC FOCUS 56
5 INDUSTRY TRENDS 57
5.1 PORTER’S FIVE FORCES ANALYSIS 57
5.1.1 BARGAINING POWER OF SUPPLIERS 58
5.1.2 BARGAINING POWER OF BUYERS 58
5.1.3 THREAT OF NEW ENTRANTS 58
5.1.4 THREAT OF SUBSTITUTES 59
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 59
5.2 MACROECONOMIC OUTLOOK 59
5.2.1 INTRODUCTION 59
5.2.2 GDP TRENDS AND FORECAST 59
5.3 SUPPLY CHAIN ANALYSIS 62
5.4 VALUE CHAIN ANALYSIS 63
5.5 ECOSYSTEM ANALYSIS 65
5.5.1 BODY FLUID ANALYSIS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 65
5.6 PRICING ANALYSIS 66
5.6.1 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS,
BY KEY PLAYER, 2024–2026 66
5.6.2 AVERAGE SELLING PRICE OF BODY FLUID ANALYSIS PRODUCTS, BY REGION, 2024–2026 67
5.7 TRADE ANALYSIS 68
5.7.1 IMPORT SCENARIO (HS CODE 3822) 68
5.7.2 EXPORT SCENARIO (HS CODE 3822) 69
5.8 KEY CONFERENCES & EVENTS, 2026–2027 70
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 71
5.10 INVESTMENT & FUNDING SCENARIO 71
5.11 CASE STUDY ANALYSIS 72
5.11.1 CASE STUDY 1: IMPLEMENTATION OF AUTOMATED CSF ALZHEIMER’S BIOMARKER TESTING USING ROCHE ELECSYS ASSAYS 72
5.11.2 CASE STUDY 2: IMPLEMENTATION OF AUTOMATED BODY FLUID CELL COUNTING USING BECKMAN COLTER UNICEL DXH SERIES 73
5.11.3 CASE STUDY 3: POINT-OF-CARE TESTING FOR PLEURAL, PERITONEAL, AND CSF ANALYSIS 73
5.12 IMPACT OF US TARIFFS—BODY FLUID ANALYSIS MARKET 74
5.12.1 INTRODUCTION 74
5.12.2 KEY TARIFF RATES 74
5.12.3 PRICE IMPACT ANALYSIS 75
5.12.4 IMPACT ON COUNTRIES/REGIONS 75
5.12.4.1 North America 75
5.12.4.2 Europe 75
5.12.4.3 Asia Pacific 76
5.12.5 IMPACT ON END-USE INDUSTRIES 76
5.12.5.1 Diagnostic laboratories 76
5.12.5.2 Hospital laboratories 76
5.12.5.3 Forensic laboratories 77
5.12.5.4 Academic & research institutes 77
5.12.5.5 Pharmaceutical & biotechnology companies 77
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 78
6.1 KEY EMERGING TECHNOLOGIES 78
6.1.1 FLOW CYTOMETRY 78
6.1.2 PCR 78
6.2 COMPLEMENTARY TECHNOLOGIES 79
6.2.1 BIOINFORMATICS & DATA ANALYTICS PLATFORMS 79
6.3 ADJACENT TECHNOLOGIES 80
6.3.1 DIGITAL PCR (DPCR) 80
6.4 TECHNOLOGY/PRODUCT ROADMAP 80
6.5 PATENT ANALYSIS 82
6.5.1 LIST OF MAJOR PATENTS 83
6.6 FUTURE APPLICATIONS 84
6.7 IMPACT OF AI/GENERATIVE AI ON BODY FLUID ANALYSIS MARKET 85
6.7.1 INTRODUCTION 85
6.7.2 TOP USE CASES AND MARKET POTENTIAL 86
6.7.3 KEY COMPANIES IMPLEMENTING AI 87
6.7.4 FUTURE OF AI 87
 
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 88
7.1 REGIONAL REGULATIONS AND COMPLIANCE 88
7.1.1 REGULATORY ANALYSIS 88
7.1.1.1 North America 88
7.1.1.1.1 US 88
7.1.1.1.2 Canada 88
7.1.1.2 Europe 88
7.1.1.2.1 Germany 89
7.1.1.2.2 UK 89
7.1.1.2.3 France 90
7.1.1.2.4 Italy 90
7.1.1.3 Asia Pacific 90
7.1.1.3.1 China 90
7.1.1.3.2 Japan 90
7.1.1.3.3 India 91
7.1.1.4 Latin America 91
7.1.1.4.1 Brazil 91
7.1.1.4.2 Mexico 92
7.1.1.5 Middle East 92
7.1.1.5.1 Africa 92
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
7.2 SUSTAINABILITY INITIATIVES 94
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN BODY FLUID ANALYSIS MARKET 94
7.2.1.1 Eco-friendly Initiatives 95
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 96
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 97
8.1 DECISION-MAKING PROCESS 97
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 97
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 97
8.2.2 BUYING CRITERIA 98
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 99
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 100
8.5 MARKET PROFITABILITY 102
8.5.1 REVENUE POTENTIAL 102
8.5.2 COST DYNAMICS 102
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 103
 
9 BODY FLUID ANALYSIS MARKET, BY PRODUCT 104
9.1 INTRODUCTION 105
9.2 CONSUMABLES 105
9.2.1 ONGOING INNOVATIONS IN BODY FLUID ANALYSIS TO SPUR GROWTH 105
9.3 INSTRUMENTS 109
9.3.1 TECHNOLOGICAL ADVANCEMENTS TO FOSTER MARKET GROWTH 109
10 BODY FLUID ANALYSIS MARKET, BY TECHNOLOGY 112
10.1 INTRODUCTION 113
10.2 MICROSCOPIC EXAMINATION 113
10.2.1 GROWING ADOPTION OF AUTOMATED AND DIGITAL MICROSCOPY TO DRIVE MARKET 113
10.3 CLINICAL CHEMISTRY 117
10.3.1 RISING DEMAND FOR RAPID AND ACCURATE BIOCHEMICAL ASSESSMENT FUELS ADOPTION OF CLINICAL CHEMISTRY TECHNOLOGY 117
10.4 FLOW CYTOMETRY 120
10.4.1 ADVANCEMENTS IN MULTIPARAMETRIC ANALYSIS AND AUTOMATION DRIVE THE MARKET GROWTH 120
10.5 IMMUNOASSAY 122
10.5.1 INCREASING USE OF IMMUNOASSAYS IN CANCER AND INFECTIOUS DISEASE TESTING TO AID GROWTH 122
10.6 POLYMERASE CHAIN REACTION 125
10.6.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH 125
10.7 OTHER TECHNOLOGIES 128
11 BODY FLUID ANALYSIS MARKET, BY TYPE 131
11.1 INTRODUCTION 132
11.2 COLLECTION DEVICES 132
11.2.1 RISING DEMAND FOR ACCURATE SPECIMEN COLLECTION AND HANDLING TO PROMOTE GROWTH 132
11.3 DIAGNOSTIC PRODUCTS 135
11.3.1 TECHNOLOGICAL ADVANCEMENTS TO AUGMENT GROWTH 135
12 BODY FLUID ANALYSIS MARKET, BY FLUID TYPE 139
12.1 INTRODUCTION 140
12.2 CEREBROSPINAL FLUID 140
12.2.1 INCREASING BURDEN OF NEUROLOGICAL DISORDERS SUPPORTS MARKET GROWTH 140
12.3 PLEURAL FLUID 142
12.3.1 TECHNOLOGICAL ADVANCEMENTS IMPROVING DIAGNOSTIC ACCURACY OF PLEURAL FLUID TESTING TO DRIVE MARKET 142
 
12.4 PERITONEAL FLUID 145
12.4.1 RISING PREVALENCE OF LIVER DISORDERS AND MALIGNANT ASCITES DRIVES MARKET 145
12.5 SYNOVIAL FLUID 148
12.5.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET 148
12.6 SEMEN 150
12.6.1 DECLINING MALE REPRODUCTIVE HEALTH DRIVING DEMAND FOR SEMEN ANALYSIS 150
12.7 PERICARDIAL FLUID 153
12.7.1 GROWING UTILIZATION OF PERICARDIAL FLUID TESTING IN CLINICAL PRACTICES TO DRIVE MARKET 153
13 BODY FLUID ANALYSIS MARKET VOLUME ANALYSIS, BY FLUID TYPE (NUMBER OF TESTS) 156
14 BODY FLUID ANALYSIS MARKET, BY APPLICATION 157
14.1 INTRODUCTION 158
14.2 CLINICAL DIAGNOSTICS 158
14.2.1 INFECTIOUS DISEASES 161
14.2.1.1 Rising burden of infectious diseases drives adoption of body fluid analysis 161
14.2.2 INFLAMMATORY DISEASES 164
14.2.2.1 Growing burden of autoimmune and inflammatory diseases supports market growth 164
14.2.3 CANCER 167
14.2.3.1 Rising burden of cancer to fuel growth 167
14.2.4 OTHER DISEASES 169
14.3 FORENSICS 172
14.3.1 GROWING UTILIZATION OF BODY FLUID ANALYSIS IN FORENSIC AND MEDICO-LEGAL INVESTIGATIONS TO SUPPORT MARKET 172
14.4 RESEARCH 175
14.4.1 INCREASING USE OF BODY FLUID ANALYSIS IN BIOMEDICAL RESEARCH AND BIOMARKER DISCOVERY TO BOOST MARKET 175
15 BODY FLUID ANALYSIS MARKET, BY END USER 178
15.1 INTRODUCTION 179
15.2 HOSPITAL LABORATORIES 179
15.2.1 RISING HEALTHCARE INVESTMENT TO CONTRIBUTE TO GROWTH 179
15.3 DIAGNOSTIC LABORATORIES 182
15.3.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET 182
15.4 FORENSIC LABORATORIES 185
15.4.1 ADVANCEMENTS IN FORENSIC TESTING AND LABORATORY INFORMATICS SUPPORT MARKET GROWTH 185
15.5 ACADEMIC & RESEARCH INSTITUTES 187
15.5.1 ADVANCEMENTS IN RESEARCH TO BOOST MARKET 187
15.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 190
15.6.1 INCREASING ADOPTION OF BIOMARKER-DRIVEN DRUG DEVELOPMENT TO SUPPORT MARKET GROWTH 190
16 BODY FLUID ANALYSIS MARKET, BY REGION 193
16.1 INTRODUCTION 194
16.2 NORTH AMERICA 195
16.2.1 US 200
16.2.1.1 Presence of advanced healthcare infrastructure to augment growth 200
16.2.2 CANADA 204
16.2.2.1 Favorable government initiatives to fuel market 204
16.3 EUROPE 208
16.3.1 GERMANY 211
16.3.1.1 Increasing healthcare expenditure to advance growth 211
16.3.2 UK 216
16.3.2.1 Growing number of diagnostic centers to fuel market 216
16.3.3 FRANCE 219
16.3.3.1 Increasing demand for early disease diagnosis to augment growth 219
16.3.4 ITALY 223
16.3.4.1 Growing adoption of advanced diagnostic technologies to fuel market 223
16.3.5 SPAIN 226
16.3.5.1 Increased government initiatives to boost market 226
16.3.6 REST OF EUROPE 229
16.4 ASIA PACIFIC 233
16.4.1 CHINA 237
16.4.1.1 Rising public access to modern healthcare to spur growth 237
16.4.2 JAPAN 240
16.4.2.1 Universal healthcare reimbursement policy to foster growth 240
16.4.3 INDIA 243
16.4.3.1 Increased government investments for healthcare sector to bolster growth 243
16.4.4 REST OF ASIA PACIFIC 247
16.5 LATIN AMERICA 252
16.5.1 RISING DISEASE INCIDENCE AND HEALTHCARE INFRASTRUCTURAL IMPROVEMENTS TO DRIVE MARKET 252
16.6 MIDDLE EAST & AFRICA 256
16.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH 256
 
17 COMPETITIVE LANDSCAPE 260
17.1 INTRODUCTION 260
17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 260
17.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN BODY FLUID ANALYSIS MARKET 260
17.3 REVENUE ANALYSIS, 2023–2025 262
17.4 MARKET SHARE ANALYSIS, 2025 263
17.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 263
17.4.2 US MARKET SHARE ANALYSIS, 2025 265
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 265
17.5.1 STARS 265
17.5.2 EMERGING LEADERS 265
17.5.3 PERVASIVE PLAYERS 266
17.5.4 PARTICIPANTS 266
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 267
17.5.5.1 Company footprint 267
17.5.5.2 Region footprint 267
17.5.5.3 Product footprint 268
17.5.5.4 Type footprint 269
17.5.5.5 Application footprint 269
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 270
17.6.1 PROGRESSIVE COMPANIES 270
17.6.2 RESPONSIVE COMPANIES 270
17.6.3 DYNAMIC COMPANIES 270
17.6.4 STARTING BLOCKS 270
17.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 272
17.6.5.1 Detailed list of key startups/SMEs 272
17.6.5.2 Competitive benchmarking of startups/SMEs 272
17.7 COMPANY VALUATION & FINANCIAL METRICS 273
17.7.1 FINANCIAL METRICS 273
17.7.2 COMPANY VALUATION 274
17.8 PRODUCT COMPARISON 274
17.9 COMPETITIVE SCENARIO 275
17.9.1 PRODUCT LAUNCHES & APPROVALS 275
17.9.2 DEALS 276
17.9.3 EXPANSIONS 277
 
18 COMPANY PROFILES 278
18.1 KEY PLAYERS 278
18.1.1 DANAHER 278
18.1.1.1 Business overview 278
18.1.1.2 Products offered 279
18.1.1.3 Recent developments 281
18.1.1.3.1 Deals 281
18.1.1.4 MnM view 281
18.1.1.4.1 Key strengths 281
18.1.1.4.2 Strategic choices 282
18.1.1.4.3 Weaknesses and competitive threats 282
18.1.2 F. HOFFMANN-LA ROCHE LTD 283
18.1.2.1 Business overview 283
18.1.2.2 Products offered 284
18.1.2.3 Recent developments 286
18.1.2.3.1 Product launches & approvals 286
18.1.2.4 MnM view 286
18.1.2.4.1 Key strengths 286
18.1.2.4.2 Strategic choices 286
18.1.2.4.3 Weaknesses and competitive threats 287
18.1.3 BECTON, DICKINSON AND COMPANY (BD) 288
18.1.3.1 Business overview 288
18.1.3.2 Products offered 289
18.1.3.3 MnM view 291
18.1.3.3.1 Key strengths 291
18.1.3.3.2 Strategic choices 291
18.1.3.3.3 Weaknesses and competitive threats 291
18.1.4 ABBOTT 292
18.1.4.1 Business overview 292
18.1.4.2 Products offered 293
18.1.4.3 MnM view 294
18.1.4.3.1 Key strengths 294
18.1.4.3.2 Strategic choices 294
18.1.4.3.3 Weaknesses & competitive threats 294
18.1.5 THERMO FISHER SCIENTIFIC INC. 295
18.1.5.1 Business overview 295
18.1.5.2 Products offered 296
18.1.5.3 Recent developments 298
18.1.5.3.1 Expansions 298
18.1.5.4 MnM view 298
18.1.5.4.1 Key strengths 298
18.1.5.4.2 Strategic choices 298
18.1.5.4.3 Weaknesses and competitive threats 298
18.1.6 SIEMENS HEALTHINEERS AG 299
18.1.6.1 Business overview 299
18.1.6.2 Products offered 300
18.1.6.3 Recent developments 302
18.1.6.3.1 Deals 302
18.1.6.3.2 Expansions 302
18.1.7 BIOMÉRIEUX 303
18.1.7.1 Business overview 303
18.1.7.2 Products offered 305
18.1.8 SYSMEX CORPORATION 306
18.1.8.1 Business overview 306
18.1.8.2 Products offered 307
18.1.8.3 Recent developments 308
18.1.8.3.1 Deals 308
18.1.9 BIO-RAD LABORATORIES 309
18.1.9.1 Business overview 309
18.1.9.2 Products offered 310
18.1.10 QIAGEN 312
18.1.10.1 Business overview 312
18.1.10.2 Products offered 313
18.1.10.3 Recent developments 314
18.1.10.3.1 Product launches and approvals 314
18.1.11 REVVITY 315
18.1.11.1 Business overview 315
18.1.11.2 Products offered 317
18.1.12 DIASORIN S.P.A. 318
18.1.12.1 Business overview 318
18.1.12.2 Products offered 319
18.1.13 HORIBA, LTD. 321
18.1.13.1 Business overview 321
18.1.13.2 Products offered 323
18.2 OTHER PLAYERS 324
18.2.1 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. 324
18.2.2 VIRCELL S.L. 325
18.2.3 FUJIREBIO 326
18.2.4 ERBA GROUP 327
18.2.5 GUANGZHOU WONDFO BIOTECH CO., LTD. 328
18.2.6 MESO SCALE DIAGNOSTICS, LLC 329
18.2.7 RANDOX LABORATORIES LTD. 330
18.2.8 AMPRION DIAGNOSTICS 331
18.2.9 ATILA BIOSYSTEMS 332
18.2.10 QUANTERIX 333
18.2.11 ALAMAR BIOSCIENCES 334
18.2.12 GENEPROOF 335
19 RESEARCH METHODOLOGY 336
19.1 RESEARCH DATA 336
19.1.1 SECONDARY DATA 337
19.1.1.1 List of secondary sources 337
19.1.1.2 Key data from secondary sources 338
19.1.2 PRIMARY DATA 338
19.1.2.1 List of primary sources 339
19.1.2.2 Key data from primary sources 339
19.1.2.3 Key industry insights 340
19.1.2.4 Breakdown of primary interviews 341
19.2 MARKET SIZE ESTIMATION 341
19.2.1 TOTAL MARKET SIZE: BODY FLUID ANALYSIS MARKET 341
19.2.2 BOTTOM-UP APPROACH 341
19.2.2.1 Approach 1: Revenue estimation of key players 342
19.2.2.2 Approach 2: Study of annual reports and investor presentations 342
19.2.2.3 Approach 3: Primary interviews 342
19.2.2.4 Growth forecast 343
19.2.2.5 CAGR projections 343
19.2.3 TOP-DOWN APPROACH 344
19.3 DATA TRIANGULATION 345
19.4 RESEARCH ASSUMPTIONS 345
19.4.1 STUDY-RELATED ASSUMPTIONS 345
19.5 STUDY ASSUMPTIONS 346
19.5.1 PARAMETRIC ASSUMPTIONS 346
19.5.2 GROWTH RATE ASSUMPTIONS 347
19.6 RESEARCH LIMITATIONS 347
19.7 RISK ASSESSMENT 347
20 APPENDIX 348
20.1 DISCUSSION GUIDE 348
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 352
20.3 CUSTOMIZATION OPTIONS 354
20.4 RELATED REPORTS 354
20.5 AUTHOR DETAILS 355